Evidence map›Paper›PMID 34277651›Full record

ReviewFrontiers in medicine2021

The Application of Induced Pluripotent Stem Cells Against Liver Diseases: An Update and a Review.

Lei Zhang, Ke Pu, Xiaojun Liu, Sarah Da Won Bae, Romario Nguyen, Suyang Bai, Yi Li, Liang Qiao

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. iPSC-derived cells for whole liver bioengineering.Frontiers in bioengineering and biotechnology · 2024
    Review
  10. Review
  11. Review
  12. [Current status, challenges and reflections on stem cell therapy for liver diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Lei ZhangThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Ke PuDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.
Xiaojun LiuDepartment of Medical Oncology, The First Hospital of Lanzhou University, Lanzhou, China.
Sarah Da Won BaeStorr Liver Centre, Westmead Institute for Medical Research, University of Sydney at Westmead Clinical School, Westmead, NSW, Australia.
Romario NguyenStorr Liver Centre, Westmead Institute for Medical Research, University of Sydney at Westmead Clinical School, Westmead, NSW, Australia.
Suyang BaiDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.
Yi LiDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.
Liang QiaoStorr Liver Centre, Westmead Institute for Medical Research, University of Sydney at Westmead Clinical School, Westmead, NSW, Australia.
First Hospital of Lanzhou University · CNLanzhou University · CNWestmead Institute for Medical Research · AUWestmead Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver diseases are a major health concern globally, and are associated with poor survival and prognosis of patients. This creates the need for patients to accept the main alternative treatment of liver transplantation to prevent progression to end-stage liver disease. Investigation of the molecular mechanisms underpinning complex liver diseases and their pathology is an emerging goal of stem cell scope. Human induced pluripotent stem cells (hiPSCs) derived from somatic cells are a promising alternative approach to the treatment of liver disease, and a prospective model for studying complex liver diseases. Here, we review hiPSC technology of cell reprogramming and differentiation, and discuss the potential application of hiPSC-derived liver cells, such as hepatocytes and cholangiocytes, in refractory liver-disease modeling and treatment, and drug screening and toxicity testing. We also consider hiPSC safety in clinical applications, based on genomic and epigenetic alterations, tumorigenicity, and immunogenicity.

Indexed as

clinical applicationHLCsIPS cellliver diseaseprimary human hepatocytes

Identifiers

PMID34277651
PMCPMC8280311
OpenAlexW3179112927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.